Symphogen Appoints Jørgen Petersen as Chief Development Officer

-Antibody Development Veteran to Oversee the Clinical Advancement of Symphogen`s
Novel Antibody Pipeline-
COPENHAGEN--(Business Wire)--
Symphogen A/S today announced that Jørgen Petersen, M.D., DMSc, has joined the
company`s executive management team as Chief Development Officer. Dr. Petersen
comes to Symphogen from Genmab A/S.

"As Symphogen is progressing its novel pipeline towards later stage clinical
programs we have significantly strengthened our executive leadership team with
the recruitment of Jørgen Petersen," said Kirsten Drejer, Ph.D., CEO of
Symphogen. "As co-founder of Genmab and an immunologist and rheumatologist,
Jørgen brings to Symphogen an exceptional scientific and medical background.
While at Genmab, Jørgen developed a deep expertise in executing successful
clinical and regulatory strategies having facilitated the advancement of
multiple product candidates spanning from preclinical development to BLA
submission."

Dr. Petersen joined Genmab A/S as Medical Director in 2002. He has since held
several positions of increasing responsibility to support the strategic
development of the company`s monoclonal antibody pipeline. Prior to joining
Genmab, Dr. Petersen was Head of Rheumatology, Rigshospitalet in Copenhagen. In
parallel with his clinical career, Dr. Petersen served as associate and full
Professor of Internal Medicine at the University of Copenhagen.

Dr. Petersen has significant international experience from his time as a
post-doctoral fellow of Molecular and Experimental Medicine at the Institute of
Scripps Clinic in La Jolla, California. Dr. Petersen has authored over 100 peer
reviewed publications and several book chapters within the fields of cellular
immunology, inflammation, rheumatology, hematology and immuno-pharmacology.

About Symphogen

Symphogen is developing superior antibody therapeutics to help people with
serious diseases. With its proprietary SymplexTM discovery and SympressTM
manufacturing platforms, the company captures the diversity and specificity of
the natural immune response in rationally designed recombinant antibody
compositions. Symphogen is maturing a diversified pipeline of internal and
partnered products across multiple indications including cancer and infectious
disease. Symphogen is a private biopharmaceutical company with more than 70
employees, based in Copenhagen, Denmark. www.symphogen.com

Symphogen:
Kirsten Drejer, +45 45 26 50 59
CEO
+45 22 10 99 59 (cell)
kd@symphogen.com
or
Media:
Karen Miller, +1 732 261 4085
kmi@symphogen.com

Copyright Business Wire 2009